- Home
- TEF vs ONC Comparison
TEF vs ONC Comparison
Compare TEF & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEF
- ONC
- Stock Information
- Founded
- TEF 1924
- ONC 2010
- Country
- TEF Spain
- ONC Switzerland
- Employees
- TEF N/A
- ONC N/A
- Industry
- TEF Telecommunications Equipment
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- TEF Telecommunications
- ONC Health Care
- Exchange
- TEF Nasdaq
- ONC Nasdaq
- Market Cap
- TEF 29.9B
- ONC 26.9B
- IPO Year
- TEF 1987
- ONC N/A
- Fundamental
- Price
- TEF $5.21
- ONC $252.78
- Analyst Decision
- TEF
- ONC Strong Buy
- Analyst Count
- TEF 0
- ONC 7
- Target Price
- TEF N/A
- ONC $326.43
- AVG Volume (30 Days)
- TEF 594.1K
- ONC 322.1K
- Earning Date
- TEF 07-30-2025
- ONC 08-06-2025
- Dividend Yield
- TEF 5.32%
- ONC N/A
- EPS Growth
- TEF N/A
- ONC N/A
- EPS
- TEF N/A
- ONC N/A
- Revenue
- TEF $44,356,895,792.00
- ONC $4,175,868,000.00
- Revenue This Year
- TEF N/A
- ONC $32.78
- Revenue Next Year
- TEF $0.17
- ONC $19.07
- P/E Ratio
- TEF N/A
- ONC N/A
- Revenue Growth
- TEF 0.72
- ONC 51.91
- 52 Week Low
- TEF $3.89
- ONC $141.31
- 52 Week High
- TEF $5.48
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- TEF 51.32
- ONC N/A
- Support Level
- TEF $5.22
- ONC N/A
- Resistance Level
- TEF $5.48
- ONC N/A
- Average True Range (ATR)
- TEF 0.05
- ONC 0.00
- MACD
- TEF -0.02
- ONC 0.00
- Stochastic Oscillator
- TEF 0.00
- ONC 0.00
About TEF Telefonica SA
Telefonica operates mobile and fixed networks in Spain (where it is the incumbent operator), the UK, Germany, Brazil, and Latin American countries. The company derives more than 30% of its revenue from Spain, close to 20% from Germany, and 20% from Brazil. Its UK operations are held through a joint venture with Virgin Media. For several years Telefonica has been simplifying its corporate structure by selling noncore assets.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.